Emily McGinnis is the Chief Patient Officer and Head of Government Affairs at Taysha Gene Therapies. Emily has worked in many roles in the biotechnology industry over 20 years, including launching innovative therapies for patients with rare neurological diseases, leading medical affairs efforts, government affairs and patient advocacy. Prior to joining Taysha in April 2020, Emily had strategic oversight of patient advocacy and government affairs at AveXis where she was instrumental in the launch of Zolgensma, a gene therapy for Spinal Muscular Atrophy (SMA). She played a key role in collaborating with advocacy on newborn screening development and implementation efforts to rapidly diagnose patients with SMA. Emily holds a master’s degree in Public Health from University of Illinois at Chicago.